Cannabinoid receptor 2 signaling does not modulate atherogenesis in mice

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Willecke, Florian ^a   Zeschky, Katharina ^a   Rodriguez, Alexandra ^a   Colberg, Christian ^a   Auwärter, Volker ^b   Kneisel, Stefan ^b   Hutter, Melanie ^b   Lozhkin, Andrey ^a   Hoppe, Natalie ^a   Wolf, Dennis ^a   von zur Mühlen, Constantin ^a   Moser, Martin ^a   Hilgendorf, Ingo ^a   Bode, Christoph ^a   Zirlik, Andreas ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; CANNABINOID 2 RECEPTOR; COLLAGEN FIBER; CYTOKINE; LIPID; LOW DENSITY LIPOPROTEIN RECEPTOR; THIOGLYCOLIC ACID; 1,1 DIMETHYLBUTYL 1 DEOXY DELTA(9) THC; 1,1-DIMETHYLBUTYL-1-DEOXY-DELTA(9)-THC; CANNABINOID; INTERCELLULAR ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ARCH; AORTA ROOT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CELL ADHESION; CHOLESTEROL DIET; CONTROLLED STUDY; HYPOBETALIPOPROTEINEMIA; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MALE; MOUSE; NONHUMAN; PERITONITIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; T LYMPHOCYTE; ANIMAL; ATHEROSCLEROSIS; C57BL MOUSE; CELL SURVIVAL; DISEASE MODEL; DRUG EFFECT; DRUG POTENTIATION; ENDOTHELIUM CELL; FEEDING BEHAVIOR; INFLAMMATION; MASS SPECTROMETRY; METABOLISM; MONOCYTE; PATHOLOGY;

MURINAE; MUS;

ANIMALS; ATHEROSCLEROSIS; CANNABINOIDS; CELL SURVIVAL; CYTOKINES; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FEEDING BEHAVIOR; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; MASS SPECTROMETRY; MICE; MICE, INBRED C57BL; MONOCYTES; RECEPTOR, CANNABINOID, CB2; SIGNAL TRANSDUCTION;

EID: 79955622635     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019405     Document Type: Article

References (47)

1. Libby P, (2002) Inflammation in atherosclerosis. Nature 420: 868-874.
2. Mach F, Steffens S, (2008) The role of the endocannabinoid system in atherosclerosis. J Neuroendocrinol 20 (Suppl 1): 53-57.
3. Zhao Y, Yuan Z, Liu Y, Xue J, Tian Y, et al. (2010) Activation of cannabinoid CB2 receptor ameliorates atherosclerosis associated with suppression of adhesion molecules. J Cardiovasc Pharmacol 55: 292-298.
4. Han KH, Lim S, Ryu J, Lee CW, Kim Y, et al. (2009) CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages. Cardiovasc Res 84: 378-386.
5. Di Marzo V, (2008) Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 7: 438-455.
6. Pacher P, Batkai S, Kunos G, (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58: 389-462.
7. Klein TW, Newton C, Larsen K, Lu L, Perkins I, et al. (2003) The cannabinoid system and immune modulation. J Leukoc Biol 74: 486-496.
8. Dol-Gleizes F, Paumelle R, Visentin V, Mares AM, Desitter P, et al. (2009) Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 29: 12-18.
9. Roche R, Hoareau L, Bes-Houtmann S, Gonthier MP, Laborde C, et al. (2006) Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes. Histochem Cell Biol 126: 177-187.
10. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, et al. (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310: 329-332.
11. Mukhopadhyay P, Batkai S, Rajesh M, Czifra N, Harvey-White J, et al. (2007) Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol 50: 528-536.
12. Rajesh M, Mukhopadhyay P, Batkai S, Hasko G, Liaudet L, et al. (2007) CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol 293: H2210-2218.
13. Zhang M, Martin BR, Adler MW, Razdan RK, Jallo JI, et al. (2007) Cannabinoid CB(2) receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model. J Cereb Blood Flow Metab 27: 1387-1396.
14. Murikinati S, Juttler E, Keinert T, Ridder DA, Muhammad S, et al. (2010) Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. FASEB J 24: 788-798.
15. Guindon J, Hohmann AG, (2009) The endocannabinoid system and pain. CNS Neurol Disord Drug Targets 8: 403-421.
16. Montecucco F, Lenglet S, Braunersreuther V, Burger F, Pelli G, et al. (2009) CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion. J Mol Cell Cardiol 46: 612-620.
17. Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, et al. (2005) Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 434: 782-786.
18. Bavendiek U, Zirlik A, LaClair S, MacFarlane L, Libby P, et al. (2005) Atherogenesis in mice does not require CD40 ligand from bone marrow-derived cells. Arterioscler Thromb Vasc Biol 25: 1244-1249.
19. Zirlik A, Maier C, Gerdes N, MacFarlane L, Soosairajah J, et al. (2007) CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1. Circulation 115: 1571-1580.
20. Missiou A, Kostlin N, Varo N, Rudolf P, Aichele P, et al. (2010) Tumor necrosis factor receptor-associated factor 1 (TRAF1) deficiency attenuates atherosclerosis in mice by impairing monocyte recruitment to the vessel wall. Circulation 121: 2033-2044.
21. Zirlik A, Bavendiek U, Libby P, MacFarlane L, Gerdes N, et al. (2007) TRAF-1,-2,-3,-5, and-6 are induced in atherosclerotic plaques and differentially mediate proinflammatory functions of CD40L in endothelial cells. Arterioscler Thromb Vasc Biol 27: 1101-1107.
22. Missiou A, Kostlin N, Varo N, Rudolf P, Aichele P, et al. (2010) Tumor necrosis factor receptor-associated factor 1 (TRAF1) deficiency attenuates atherosclerosis in mice by impairing monocyte recruitment to the vessel wall. Circulation 121: 2033-2044.
23. Montecucco F, Burger F, Mach F, Steffens S, (2008) CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. Am J Physiol Heart Circ Physiol 294: H1145-1155.
24. Sacerdote P, Massi P, Panerai AE, Parolaro D, (2000) In vivo and in vitro treatment with the synthetic cannabinoid CP55, 940 decreases the in vitro migration of macrophages in the rat: involvement of both CB1 and CB2 receptors. J Neuroimmunol 109: 155-163.
25. Netherland CD, Pickle TG, Bales A, Thewke DP, (2010) Cannabinoid receptor type 2 (CB2) deficiency alters atherosclerotic lesion formation in hyperlipidemic Ldlr-null mice. Atherosclerosis 213: 102-108.
26. Freeman-Anderson NE, Pickle TG, Netherland CD, Bales A, Buckley NE, et al. (2008) Cannabinoid (CB2) receptor deficiency reduces the susceptibility of macrophages to oxidized LDL/oxysterol-induced apoptosis. J Lipid Res 49: 2338-2346.
27. Montecucco F, Matias I, Lenglet S, Petrosino S, Burger F, et al. (2009) Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis. Atherosclerosis 205: 433-441.
28. Sugamura K, Sugiyama S, Fujiwara Y, Matsubara J, Akiyama E, et al. (2010) Cannabinoid 1 receptor blockade reduces atherosclerosis with enhances reverse cholesterol transport. J Atheroscler Thromb 17: 141-147.
29. Sugamura K, Sugiyama S, Nozaki T, Matsuzawa Y, Izumiya Y, et al. (2009) Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation 119: 28-36.
30. Huffman JW, (2000) The search for selective ligands for the CB2 receptor. Curr Pharm Des 6: 1323-1337.
31. Huffman JW, Liddle J, Yu S, Aung MM, Abood ME, et al. (1999) 3-(1′,1′-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem 7: 2905-2914.
32. Patel HJ, Birrell MA, Crispino N, Hele DJ, Venkatesan P, et al. (2003) Inhibition of guinea-pig and human sensory nerve activity and the cough reflex in guinea-pigs by cannabinoid (CB2) receptor activation. Br J Pharmacol 140: 261-268.
33. Defer N, Wan J, Souktani R, Escoubet B, Perier M, et al. (2009) The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy. FASEB J 23: 2120-2130.
34. Xu H, Cheng CL, Chen M, Manivannan A, Cabay L, et al. (2007) Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis. J Leukoc Biol 82: 532-541.
35. Jonsson KO, Persson E, Fowler CJ, (2006) The cannabinoid CB2 receptor selective agonist JWH133 reduces mast cell oedema in response to compound 48/80 in vivo but not the release of beta-hexosaminidase from skin slices in vitro. Life Sci 78: 598-606.
36. Shimada K, (2009) Immune system and atherosclerotic disease: heterogeneity of leukocyte subsets participating in the pathogenesis of atherosclerosis. Circ J 73: 994-1001.
37. Galkina E, Ley K, (2009) Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol 27: 165-197.
38. Yuan M, Kiertscher SM, Cheng Q, Zoumalan R, Tashkin DP, et al. (2002) Delta 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J Neuroimmunol 133: 124-131.
39. Zhu LX, Sharma S, Stolina M, Gardner B, Roth MD, et al. (2000) Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol 165: 373-380.
40. Braunersreuther V, Mach F, (2006) Leukocyte recruitment in atherosclerosis: potential targets for therapeutic approaches? Cell Mol Life Sci 63: 2079-2088.
41. Weber C, Zernecke A, Libby P, (2008) The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 8: 802-815.
42. Miller AM, Stella N, (2008) CB2 receptor-mediated migration of immune cells: it can go either way. Br J Pharmacol 153: 299-308.
43. Smith SR, Denhardt G, Terminelli C, (2001) The anti-inflammatory activities of cannabinoid receptor ligands in mouse peritonitis models. Eur J Pharmacol 432: 107-119.
44. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, et al. (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48: 443-450.
45. Showalter VM, Compton DR, Martin BR, Abood ME, (1996) Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278: 989-999.
46. Hillard CJ, Manna S, Greenberg MJ, DiCamelli R, Ross RA, et al. (1999) Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther 289: 1427-1433.
47. Murikinati S, Juttler E, Keinert T, Ridder DA, Muhammad S, et al. (2010) Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. FASEB J 24: 788-798.